CARVYKTI® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other treatment has not worked or has stopped working. CARVYKTI® is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells.

  • SIGN UP FOR UPDATES
  • US Healthcare Professionals
Logo
  • Home
    ABOUT
    CARVYKTI®
    What is CARVYKTI®?
    How CARVYKTI® Works
    Clinical Efficacy
    Safety Profile
    RECEIVING CARVYKTI®
    Treatment
    Patient Eligibility
    CARVYKTI® Treatment Process
    Planning for CARVYKTI® Treatment
    RESOURCES
    AND SUPPORT
    MyCARVYKTI® Patient Support Program
    Patient Resources
    Care Partner Resources
    PATIENT AND
    CARE PARTNER STORIES
    FIND A CERTIFIED
    TREATMENT CENTER
    Sign up for updates
  • IMPORTANT SAFETY INFORMATION
    PRESCRIBING INFORMATION
    Prescribing Information—English PDFPrescribing Information—Spanish PDF
    MEDICATION GUIDE
    REMS PROGRAM
    Resources in more Languages
    For Us Patients & Care Partners
    VISIT US HEALTHCARE PROFESSIONAL SITE
Signup banner imageSignup banner mobile image

WE WANT TO HELP YOU STAY INFORMED ABOUT CARVYKTI® THROUGHOUT YOUR TREATMENT JOURNEY

Tell us a little bit about yourself to receive relevant communications and resources we think may be helpful to you.
The information you provide will be used by Janssen Biotech, Inc., our affiliates, and our service providers to send you information and updates about CARVYKTI® and multiple myeloma, as well as communications to support you at certain points throughout the treatment experience. Our Privacy Policy further governs the use of information you provide. By providing the information and selecting the SUBMIT button, you indicate that you have read, understand, and agree with these terms.
 
12345

My name is...